Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Editas Medicine (NQ: EDIT ) 3.710 +0.030 (+0.82%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,547,340 Open 3.720 Bid (Size) 3.720 (50) Ask (Size) 3.770 (31) Prev. Close 3.680 Today's Range 3.675 - 3.786 52wk Range 3.620 - 11.69 Shares Outstanding 81,632,619 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Editas Medicine to Participate in Upcoming Investor Conferences August 28, 2024 From Editas Medicine, Inc. Via GlobeNewswire Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday August 08, 2024 Via Benzinga Performance YTD -62.83% -62.83% 1 Month -31.55% -31.55% 3 Month -28.24% -28.24% 6 Month -63.12% -63.12% 1 Year -58.96% -58.96% More News Read More Editas Medicine Announces Second Quarter 2024 Results and Business Updates August 07, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update July 31, 2024 From Editas Medicine, Inc. Via GlobeNewswire Unveiling 5 Analyst Insights On Editas Medicine June 18, 2024 Via Benzinga The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts May 30, 2024 Via Benzinga 3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition July 17, 2024 Via InvestorPlace 3 Profitable CRISPR Stocks Earning Analysts’ Praise July 09, 2024 Via InvestorPlace The 3 Best Gene Editing Stocks to Buy in July 2024 July 08, 2024 Via InvestorPlace Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich June 26, 2024 Via InvestorPlace 3 Gene Editing Stocks That Could Make Your Grandchildren Rich June 25, 2024 Via InvestorPlace Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress June 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress June 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential May 30, 2024 Via InvestorPlace Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June May 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting May 10, 2024 From Editas Medicine, Inc. Via GlobeNewswire 1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? May 09, 2024 Via The Motley Fool EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Editas Medicine Announces First Quarter 2024 Results and Business Updates May 08, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events May 02, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration May 01, 2024 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting April 22, 2024 From Editas Medicine, Inc. Via GlobeNewswire 1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. March 07, 2024 Via The Motley Fool 1 Beaten-Down Stock With 55% Upside, According to Wall Street March 04, 2024 Via The Motley Fool Why Editas Medicine Stock Soared as Much as 42% Higher This Week March 02, 2024 Via The Motley Fool Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
